|
Press Releases |
|
 |
|
Friday, March 7, 2025 |
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million |
OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2024 (the 'Year'), reporting record-high revenue and healthy net profit despite the challenging business landscape. more info >> |
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天宣佈截至截至2024年12月31日止年度(「年度」)的全年業績。 more info >> |
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙 |
专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(“业聚医疗”或“集团”;股份代号:6929)今天宣布截至截至2024年12月31日止年度(“年度”)的全年业绩。 more info >> |
|
Friday, August 16, 2024 |
|
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024 |
OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges. more info >> |
|
业聚医疗2024年上半年纯利达1,880万美元 |
专营经皮冠状动脉介入治疗(PCI)及经皮腔内血管成形术(PTA)手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司(「业聚医疗」或「集团」;股份代号:6929)今天宣布截至2024年6月30日止六个月(「报告期」)的中期业绩。 more info >> |
|
業聚醫療2024年上半年純利達1,880萬美元 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天宣佈截至2024年6月30日止六個月(「報告期」)的中期業績。 more info >> |
|
Wednesday, April 24, 2024 |
|
业聚医疗合资企业在中国内地启动TricValve临床试验 |
more info >> |
|
業聚醫療合資企業在中國內地啟動TricValve臨床試驗 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929)今天公佈,其合資企業業聚培福有限公司(「業聚培福」)旗下用作治療血流動力學相關的三尖瓣功能不全和腔靜脈回流的產品——TricValve經導管雙腔靜脈瓣膜系統(「TricValve」),已於2024年4月22日在中國內地展開臨床試驗。 more info >> |
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China |
OrbusNeich Medical Group Holdings Limited announced today that the Group's joint venture OrbusNeich P+F Company Limited ("ON P&F") has commenced the clinical trial for the TricValve Transcatheter Bicaval Valve System ("TricValve"), to treat patients with hemodynamically relevant tricuspid insufficiency and caval reflux, on April 22, 2024 across Mainland China. more info >> |
|
Thursday, March 7, 2024 |
|
業聚醫療收入純利雙雙創新高 分別約1.54億美元及4,510萬美元 建議派發末期股息每股10港仙 |
專營經皮冠狀動脈介入治療(PCI)及經皮腔內血管成形術(PTA)手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司(「業聚醫療」或「集團」;股份代號:6929),今天公佈截至2023年12月31日止年度的全年業績。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 15:33 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 13, 2025 15:05 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 15:00: JST
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 13, 2025 14:53 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 13, 2025 14:18 HKT/SGT
|
|
|
China Lilang Announces 2025 Interim Results
Aug 13, 2025 14:15 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 13, 2025 14:13 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT/SGT
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 12:00 HKT/SGT
|
|
|
AI Inference vs. AI Training: What Are the Differences?
Aug 13, 2025 11:00 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 13, 2025 10:15 HKT/SGT
|
|
|
首程控股(0697.HK)抽取88位幸運觀眾現場觀賽 深度參與世界人形機器人運動會
Aug 13, 2025 09:58 HKT/SGT
|
|
|
首程控股(0697.HK)抽取88位幸运观众现场观赛 深度参与世界人形机器人运动会
Aug 13, 2025 09:43 HKT/SGT
|
|
|
康基醫療收到由董事長鍾鳴、TPG及卡塔爾投資局(QIA)牽頭財團提出之私有化要約 助力公司實現長遠願景
Aug 13, 2025 09:27 HKT/SGT
|
|
|
康基医疗收到由董事长钟鸣、TPG及卡塔尔投资局(QIA)牵头财团提出的私有化要约 助力公司实现长远愿景
Aug 13, 2025 09:27 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|